Cargando…

Testing for COVID-19 in lung cancer patients

Detalles Bibliográficos
Autores principales:	Passaro, A., Peters, S., Mok, T.S.K., Attili, I., Mitsudomi, T., de Marinis, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144604/ https://www.ncbi.nlm.nih.gov/pubmed/32278879 http://dx.doi.org/10.1016/j.annonc.2020.04.002

Ejemplares similares

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
por: Gridelli, C., et al.
Publicado: (2021)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
por: Spitaleri, G., et al.
Publicado: (2023)

Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model
por: de Marinis, Filippo, et al.
Publicado: (2020)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey
por: Catania, Chiara, et al.
Publicado: (2020)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
por: Passaro, Antonio, et al.
Publicado: (2021)

Severity of COVID-19 in patients with lung cancer: evidence and challenges
por: Passaro, Antonio, et al.
Publicado: (2021)

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
por: Attili, Ilaria, et al.
Publicado: (2022)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
por: Attili, Ilaria, et al.
Publicado: (2023)

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
por: Passaro, Antonio, et al.
Publicado: (2021)

Incorporating atezolizumab in the adjuvant setting of non-small cell lung cancer: key discussion points from an expert multidisciplinary panel by Italian Association of Thoracic Oncology
por: de Marinis, Filippo, et al.
Publicado: (2022)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
por: Kris, Mark G., et al.
Publicado: (2023)

Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
por: Suda, Kenichi, et al.
Publicado: (2020)

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
por: Uramoto, H, et al.
Publicado: (2007)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Lungs after COVID-19: Evolving Knowledge of Post–COVID-19 Interstitial Lung Disease
por: Aronson, Kerri I., et al.
Publicado: (2021)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
por: Gridelli, Cesare, et al.
Publicado: (2023)

PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
por: Smeltzer, M., et al.
Publicado: (2021)

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
por: Garassino, M.C., et al.
Publicado: (2021)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
por: Suda, Kenichi, et al.
Publicado: (2013)

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
por: Lambertini, Matteo, et al.
Publicado: (2020)

COVID-19 testing in the UK
por: The Lancet Respiratory Medicine
Publicado: (2020)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Involement of an acrosinlike proteinase in the sulfhydryl-induced degradation of rabbit sperm nuclear protamine
por: Zirkin, BR, et al.
Publicado: (1980)

COVID-19 puts societies to the test
por: The Lancet Public Health
Publicado: (2020)

Lung cancer surgery during COVID-19: keep calm and operate on
por: Rakovich, George
Publicado: (2022)

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
por: Fukuyama, Y., et al.
Publicado: (1997)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2020)

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
por: Kobayashi, Yoshihisa, et al.
Publicado: (2016)

The baby lung and the COVID-19 era
por: Gattinoni, Luciano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fada7g1uu1op43kleo9ao9j9fr